SBIR Phase I: A new drug discovery method to transform peptides to small molecules: proof of principle with p53-hdm2

SBIR 第一阶段：将肽转化为小分子的新药物发现方法：用 p53-hdm2 进行原理证明

• 批准号: 0944429
• 负责人: Daniel Erlanson
• 金额: --
• 依托单位: Carmot Therapeutics, Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-01-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0944429&HistoricalAwards=false
• 关键词: SBIR; Phase; new; drug; discovery

This Small Business Innovation Research (SBIR) Phase I project will advance an innovative drug discovery technology to tackle important disease targets such as protein-protein interactions. Conventional drug discovery technologies are rarely successful at identifying drugs that can disrupt protein-protein interactions. While peptides can disrupt protein-protein interactions, peptides seldom make good drugs. This proposal describes a powerful approach to transform peptides into drug-like molecules. The well-characterized and important anti-cancer target p53-hdm2 will be used as a model system. Peptide inhibitors of the p53-hdm2 interaction have been described in the literature. The objective of this Phase I proposal is to convert these peptides into drug-like molecules. Subsequently, these molecules can be further advanced into drug candidates for treating human cancers. In addition, successful completion of the proposed research will validate a transformative new drug discovery technology.The broader impacts of this research are to develop the technologies to tackle important human disease targets that are not amenable to current drug-discovery approaches. Protein-protein interactions present one of the largest untapped opportunities to develop new therapies. The technology provides a general and systematic method to tackle this target class by efficiently transforming peptides into small molecules. It has the potential to revolutionize the drug discovery process, and thus the commercial opportunity is enormous. In addition, the proposed technology will advance our understanding of drug discovery. The societal impact will be substantial, as the technology will facilitate the discovery of drugs for unmet medical needs.

这个小型企业创新研究（SBIR）第一阶段项目将推进创新药物发现技术，以解决重要的疾病靶点，如蛋白质-蛋白质相互作用。传统的药物发现技术很少能成功地识别出能够破坏蛋白质-蛋白质相互作用的药物。虽然肽可以破坏蛋白质-蛋白质相互作用，但肽很少成为好的药物。该提案描述了一种将肽转化为药物样分子的强大方法。充分表征和重要的抗癌靶点p53-hdm 2将被用作模型系统。p53-hdm 2相互作用的肽抑制剂已在文献中描述。这个I期计划的目标是将这些肽转化为药物样分子。随后，这些分子可以进一步发展为治疗人类癌症的候选药物。此外，成功完成拟议的研究将验证一种变革性的新药发现技术。这项研究的更广泛影响是开发技术，以解决目前药物发现方法无法解决的重要人类疾病目标。蛋白质-蛋白质相互作用是开发新疗法的最大未开发机会之一。该技术提供了一种通用和系统的方法，通过有效地将肽转化为小分子来解决这一目标类别。它有可能彻底改变药物发现过程，因此商业机会巨大。此外，这项技术将促进我们对药物发现的理解。社会影响将是巨大的，因为该技术将促进为未满足的医疗需求发现药物。